Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 2 1Phase 1/2 1

Status

Recruiting 4Active not recruiting 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 3Gynecologic 2Gastrointestinal 2Breast 1

Conditions

Pancreatic Neoplasms 19Carcinoma, Non-Small-Cell Lung 15Lung Neoplasms 13Urinary Bladder Neoplasms 11Ovarian Neoplasms 8Non-Muscle Invasive Bladder Neoplasms 6Neoplasm Metastasis 5Colorectal Neoplasms 5Cholangiocarcinoma 5Parkinson Disease 4, Autosomal Dominant Lewy Body 4Lymphoma, Large B-Cell, Diffuse 4Fallopian Tube Neoplasms 4Breast Neoplasms 4Biliary Tract Neoplasms 4Triple Negative Breast Neoplasms 3Nasopharyngeal Carcinoma 3Melanoma 3Recurrence 2Rectal Neoplasms 2Osteosarcoma 2Lymphoma, Follicular 2Gallbladder Neoplasms 2Colonic Neoplasms 2Carcinoma, Transitional Cell 2Bile Duct Neoplasms 2Uterine Cervical Neoplasms 1Urothelial Cancer 1Urologic Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1

Interventions

pembrolizumab 18Specimen Handling 16Magnetic Resonance Spectroscopy 11Biopsy 11Paclitaxel 8Carboplatin 8trastuzumab deruxtecan 6Pemetrexed 6Nivolumab 6Irinotecan 6Fulvestrant 6Bevacizumab 6Radiosurgery 5Leucovorin 5Gemcitabine 5Fluorouracil 5Cetuximab 5palbociclib 4Oxaliplatin 4Letrozole 4Cisplatin 4olaparib 3durvalumab 3Taxes 3Ipilimumab 3Docetaxel 3Capecitabine 3130-nm albumin-bound paclitaxel 3sacituzumab govitecan 2ribociclib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Gemcitabine × 30 days × Clear all
NCT07007559 2026-06-05

ASPEN-09-03

ALX Oncology Inc.

Phase 2 Recruiting
120 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT06917079 2026-06-02

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Phase 1 Recruiting
665 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Colorectal Neoplasms

NCT07213804 2026-05-27

FRAmework-01

Eli Lilly and Company

Phase 3 Recruiting
1,080 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms

NCT06607185 2026-05-26

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
750 enrolled
GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT05431270 2026-05-19

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Phanes Therapeutics

Phase 1/2 Recruiting
40 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡